153 results about "Medium-chain triglyceride" patented technology

A chewing gum includes a body and a coating. The body includes a gum base polymer, an oil, an active ingredient, an insoluble cellulosic material, and a buffer system. The gum base polymer includes polyvinyl acetate (PVA) in an amount ranging from 35 weight percent to 55 weight percent of the body. The oil includes medium chain triglycerides in an amount ranging from 3 weight percent to 11 weight of the body. The buffer system is present in an amount ranging from 0.1 weight percent to 8 weight percent of the body. The coating is at least partially surrounding the body.

The invention relates to the technical field of pet food antioxidants, in particular to a compound pet food antioxidant containing plant polyphenol compounds and a preparation method of the compound pet food antioxidant. 10 to 20 parts of a grape seed extract; 8 to 15 parts of a rosemary extract; 5 to 10 parts of L-ascorbyl palmitate; 5 to 10 parts of alpha-tocopheryl acetate; 3-8 parts of citric acid; 8 to 15 parts of soybean lecithin; 20 to 30 parts of medium chain triglyceride; eGCG (epigallocatechin gallate) in the green tea contains a plurality of o-dihydroxyl structures, the grape seed procyanidine has a unique C6-C3-C6 skeleton, and carnosic acid in the rosemary belongs to a diterpenoid compound. Due to the diversity of the structure, the compound can play a role in different types of free radicals and oxidation reactions, and a broad-spectrum anti-oxidation network is formed.

Disclosed is a topical anhydrous, homogenous pharmaceutical composition for treating skin disorder and wounds comprising cod liver oil, hempseed oil, monolaurin, medium chain triglycerides (“MCT”), free fatty acids, sea salt, and vegetable oil selected from the group consisting of red palm concentrate, coconut oil, and red palm oil and combination thereof and optionally fish collagen, ascorbyl palmitate, thickening agent, such as beeswax, red palm concentrate and cetyl ester.

The invention relates to the technical field of pharmaceutical preparations, in particular to a docetaxel oral self-microemulsion composition and a preparation process thereof. The docetaxel oral self-microemulsion composition is prepared from docetaxel, an oil phase, a surfactant, a cosurfactant, a stabilizer and an antioxidant, the oil phase is caprylic / capric acid mono / diglyceride, medium chain triglyceride, caprylic acid propylene glycol ester or lauric acid propylene glycol ester. The docetaxel oral self-microemulsion composition provided by the invention has relatively high drug loading capacity, good physical and chemical stability and relatively high bioavailability, and is more suitable for clinical medication.

Disclosed is a topical anhydrous, homogenous pharmaceutical composition for treating skin disorder and wounds comprising cod liver oil, hempseed oil, monolaurin, medium chain triglycerides (“MCT”), free fatty acids, sea salt, and vegetable oil selected from the group consisting of red palm concentrate, coconut oil, and red palm oil and combination thereof and optionally fish collagen, ascorbyl palmitate, thickening agent, such as beeswax, red palm concentrate and cetyl ester.

The invention discloses a satiety sugar-controlling fat-reducing composition and a preparation method and application thereof, the satiety sugar-controlling fat-reducing composition comprises hydrogel particles, a white kidney bean extract, a mulberry leaf extract, alpha-lipoic acid, L-carnitine, a lotus leaf extract, medium chain triglyceride, polyethylene glycol and sorbitol, and the composition is a tablet. The components are matched with one another to effectively adjust the leptin level, improve appetite, increase energy consumption, adjust the fat metabolism process, reduce fat accumulation, improve fat consumption, inhibit the activity of alpha-amylase, reduce the conversion of carbohydrates into fat, block heat and fat intake, promote gastrointestinal motility and enhance the immunity of the human body. The effects of remarkably reducing the fat content and the body weight are achieved.

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The invention relates to a venturi effect preparation method of a terbinafine film-forming composition, which comprises the following steps: 1) dissolving terbinafine or terbinafine hydrochloride in a solvent to obtain a medicine liquid; 2) mixing the medium chain triglyceride and the medicine liquid to obtain mixed liquid; 3) performing dry mixing with a film-forming agent to obtain a dry-mixed polymer; and 4) adding the dry-mixed polymer into the mixed liquid through a Venturi effect, and hydrating the obtained polymer. The preparation method has the advantages that the composition proportion, the preparation method and the mixing equipment are reasonable in design, the dry-mixed polymer is introduced into the liquid by utilizing the Venturi effect, lumps can be effectively crushed, the hydration effect is improved, the preparation method is efficient and economical, and the preparation time can be effectively saved and the energy consumption can be effectively reduced on the premise of ensuring the use effect.

The invention discloses a total nutrient formula food suitable for patients with nephropathy and a preparation method thereof. The formula food consists of the following components in percentage by mass: 2-3% of calcium caseinate; 12%-20% of solid starch sugar; 2%-4% of soybean oil, high oleic acid sunflower seed oil and medium chain triglyceride; 3%-5% of mineral substances; 3%-5% of vitamin; 3%-5% of a food additive; 2%-3% of fruit and vegetable powder; and the balance purified water. According to the nutritional requirements of kidney disease patients, protein and electrolyte levels are reasonably designed, the flavor of the product is adjusted, disease progression can be obviously delayed and dialysis time can be delayed when chronic kidney disease non-dialysis patients use the product on the basis of reasonable medication, and the product has excellent nutriology characteristics and patient compliance, and has good clinical application prospects. The nutritional requirements of patients can be met, and the disease progress is delayed.

The invention relates to an ophthalmic composition in an aqueous solution form. The ophthalmic composition consists of cyclosporine, medium chain triglyceride, polyoxyethylene (40) hydrogenated castor oil, polyethylene glycol 400, glycerol, sodium acetate and water. The pH value of the ophthalmic composition is close to that of tears, and the ophthalmic composition is good in medication comfort and good in stability during storage.

Provided herein are consumable compositions for methane reduction in ruminants comprising a haloalkane and a medium chain triglyceride (MCT). The use of MCT in the consumable compositions has been found to enhance the anti-methanogenic effect of the consumable compositions in ruminants. Also provided herein are methods of preparing the consumable composition and methods of administering the consumable compositions to ruminants.

The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs). In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject. The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.

The invention provides acanthopanax extract powder with excellent water solubility and taste and a preparation method of the acanthopanax extract powder, and belongs to the technical field of health care product or food preparation. The radix acanthopanacis senticosi extract powder is prepared from the following raw materials: radix acanthopanacis senticosi extract, medium chain triglyceride, a surfactant, a cosurfactant and cyclodextrin, and the mass ratio of the radix acanthopanacis senticosi extract to the medium chain triglyceride to the surfactant to the cosurfactant is (0.10 to 0.13) to (0.20 to 0.26) to (0.21 to 0.42) to (0.18 to 0.49). The ratio of the total mass of the acanthopanax extract, the medium chain triglyceride, the surfactant and the cosurfactant to the mass of the cyclodextrin is (1.5-2.5): 1, the preparation method of the acanthopanax extract powder is simple, the water solubility and bioavailability of the acanthopanax extract are remarkably improved, the application requirements of health care products and functional foods are met, and the acanthopanax extract powder is suitable for industrial production. And the transportation, storage and use convenience of the product is improved.

A composition for weight reduction and body fat reduction, its preparation method and application are disclosed, which relates to the technical field of health food. The composition includes the following components: 10-30 parts of concentrated milk protein, 10-30 parts of soybean isolated protein powder, 10-30 parts of concentrated whey protein powder, 5-15 parts of skim milk powder, 0.5-15 parts of collagen peptide, 0.1-3 parts of Agaricus bisporus extract, 0.1-3 parts of Flammulina velutipes extract, 0.1-5 parts of okra powder, 0.1-2 parts of Opuntia ficus-indica extract, 1-10 parts of medium chain triglyceride microcapsule powder, 0.1-5 parts of mango concentrated powder, 0.1-2 parts of ginger oil microcapsule powder, 0.1-2 parts of citrus powder, 0.1-5 parts of guarana extract and 0.5-2 parts of compound vitamin.

The invention discloses a composition for improving basic metabolism during low-carbon diet, and belongs to the technical field of food. The composition is prepared from the following components in parts by weight: 0.01 to 0.5 part of opuntia ficus-indica juice powder, 0.01 to 0.5 part of guarana extract, 10 to 50 parts of virgin coconut oil microcapsule powder, 1 to 10 parts of medium chain triglyceride microcapsule powder, 0.1 to 1 part of grape seed extract, 0.01 to 0.1 part of potato extract and 0.1 to 1 part of pomegranate extract. The composition can effectively improve the basal metabolic rate during a low-carbon diet period at a lower dosage. According to the innovative combination mode, the basal metabolic rate is increased, the problem of insufficient energy possibly occurring in the low-carbon diet period is relieved, and side effects and cost increase possibly caused by addition of high-dose plant extracts are avoided.

Personal care compositions are disclosed herein. In accordance with an aspect, provided is a personal care composition having a hydrocarbon having 4 to 6 carbons; a fatty ester, a fatty acid, a medium chain triglyceride, a silicone, vitamin E, or a combination of two or more thereof; and one or more surfactant, wherein the personal care composition is self-foaming.

The invention relates to the technical field of functional food preparation, and discloses solid soft sweets capable of remarkably relieving asthenopia and a preparation method of the solid soft sweets, and every 100 parts by mass of the soft sweets comprise the following components: 5.8-6.2 parts of lutein ester microcapsules, the wall material of which is starch octenyl succinate with the substitution degree of 0.02-0.04; the emulsifier is lecithin of which the purity is greater than or equal to 90%, and the particle size lt of the emulsifier is 1t; the particle size is 200 nm; 75 to 85 parts of blueberry anthocyanin-VC compound freeze-dried powder; 18 to 22 parts of lycium barbarum polysaccharide; 45 to 55 parts of galactooligosaccharide; 8 to 12 parts of medium chain triglyceride; and a colloid base material. Through collaborative design of a hydrophobic modified wall material and a gradient mixing process, a multi-level protection network of active ingredients is constructed, so that the retention rate of fat-soluble nutrients in the processing and storage period is increased to 90% or above.

The invention discloses a soft capsule coating agent which comprises the following components in percentage by mass: 40-60% of pectin, 15-30% of a humectant, 10-20% of medium chain triglyceride, 10-20% of carnauba wax, 5-10% of hydroxypropyl methyl cellulose and 0.1-10% of glycerol, wherein the humectant is prepared from at least one of sorbitol, xylitol and isomaltitol. The invention also discloses a preparation method of the soft capsule coating agent and a soft capsule containing the soft capsule coating agent. According to the soft capsule coating agent disclosed by the invention, the problems of high-temperature and high-humidity deformation and caking of soft capsules and aging of capsule skins after long-time storage can be improved, and meanwhile, the soft capsule coating agent is good in barrier property and better in protection of soft capsule products.

The present invention provides low glycemic index (GI) total nutrition formula emulsion and a preparation method therefor. The low GI total nutrition formula emulsion comprises the following raw material components in parts by weight: 10-14 parts of carbohydrates, 4-5 parts of calcium caseinate, 1.3-2 parts of dietary fiber, 0.1-0.15 part of sodium chloride, 0.1-0.12 part of sodium citrate, 0.1-0.15 part of potassium citrate, 0.15-0.2 part of magnesium chloride, 0.1-0.15 part of dipotassium hydrogen phosphate, 0.05-0.1 part of compound vitamins, 0.05-0.1 part of compound minerals, 2.5-3.6 parts of compound oil, 0.3-0.5 part of phospholipid, 0.2-0.5 part of medium chain triglyceride (MCT), 0.04-0.08 part of colloids. The preparation method comprises: preparing aqueous phases and oil phases from the raw materials step by step; mixing the aqueous phases and oil phases; and shearing, homogenizing and sterilizing the mixture to obtain the low GI total nutrition emulsion. The product features balanced and complete nutrition.

Methods improve cognitive functioning, for example, at least one of episodic memory, executive function, or language skills; supporting memory and / or recall; providing energy and / or ketones to the brain; and / or preventing and / or treating mild cognitive impairment (MCI) in an individual. A composition comprising medium chain triglycerides (MCTs) can be administered to the individual in a daily dosage providing from about 15 g to about 45 g MCTs. The MCTs can include from about 51 wt % to about 90 wt % of octanoic acid. The daily dose can be provided in at least two servings, for example, 2 or 3 servings. Each serving can provide about 15 g MCTs and can include octanoic acid and decanoic acid in a weight ratio of, for example, about 60:about 40. The individual can be 65 years or older and / or have mild cognitive impairment (MCI).

The invention discloses a W / O / W type nano-emulsion loaded with cocaine esterase as well as a preparation method and application of the W / O / W type nano-emulsion. The nano-emulsion is prepared from cocaine esterase, a phosphate buffer solution, soybean phospholipid, vitamin E polyethylene glycol succinate, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and medium chain triglyceride. The preparation method comprises the following steps: preparing the inner water phase; preparing an oil phase; slowly injecting the internal water phase into the oil phase under shearing to obtain W / O type primary emulsion; slowly adding the primary emulsion into the external water phase under shearing, and performing high-speed shearing to obtain a secondary emulsion; and performing high-pressure homogenization on the secondary emulsion to obtain the final W / O / W type nano-emulsion. The cocaine esterase is combined with the nano-emulsion for the first time, and the nano-emulsion prepared by the method has the effects of improving the temperature stability of the cocaine esterase and prolonging the in-vivo half-life period, and can be applied to rescue or prevention of cocaine acute poisoning.

The invention provides a fucoxanthin nano-emulsion preparation method, and relates to the technical field of biological medicine, fucoxanthin and medium chain triglyceride are used as raw materials to support an oil phase solvent, and the oil phase solvent is mixed with resistant dextrin, isomaltooligosacharide and fructo-oligosaccharide to prepare the fucoxanthin nano-emulsion. The oil-in-water fucoxanthin nano-emulsion with the particle size of 1-100nm is obtained by mixing water-phase solvents prepared from fucoxanthin, blood orange powder and the like, processing by a colloid mill and emulsifying and shearing by a vacuum tank, and the preparation increases the solubility of fucoxanthin, removes the unpleasant odor of fucoxanthin, reduces degradation of gastrointestinal tracts, improves the bioavailability, reduces the toxic and side effects of the fucoxanthin, improves the bioavailability of the fucoxanthin, and improves the bioavailability of the fucoxanthin. The controlled release and absorption of fucoxanthin are realized, and compared with traditional tablets and capsule products, the compliance of females, middle-aged people and old people who have difficulty in swallowing is greatly improved.

The present disclosure provides compositions and methods useful for delivering and encapsulating active agents. The compositions can comprise a polymer and a medium chain triglyceride (MCT) that comprises fatty acids having 6 to 12 carbon atoms. The compositions can encapsulate active agents including an antibacterial, a color compound, a fragrance compound, an active pharmaceutical ingredient (API), an over-the-counter (OTC) ingredient, an antioxidant, a flavinoid, an essential oil, or a combination thereof. In particular, the compositions can encapsulate essential oils. These compositions provide for the gradual and controlled release of active agents, particularly essential oils and can be used in a variety of topical products including insect repellents.

A method of treating exocrine pancreatic insufficiency includes administering to an individual in need thereof (e.g., an individual with cystic fibrosis) an effective amount of an enteral composition having a total protein consisting essentially of hydrolyzed protein and a total fat containing monoacylglycerols (MAG) that are at least about 30 wt. % of the total fat, and the total fat optionally further contains medium chain triglycerides (MCT) and / or fatty acids. In one particular non-limiting embodiment, about 60 wt. % of the total fat is from MCT and about 40 wt. % of the total fat is from MAG; in another particular non-limiting embodiment, the total fat is MAG with free fatty acids (esterified and / or bound) without MCT; and in yet another particular non-limiting embodiment, the total fat is MAG alone without MCT.

A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol / mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.

The invention belongs to the technical field of biological medicines, and particularly relates to an adjuvant influenza vaccine as well as a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS (Phosphate Buffer Solution), the adjuvant is prepared by using mixed oil and an auxiliary agent, wherein the mixed oil comprises squalene, medium chain triglyceride and alpha-tocopherol; the auxiliary agents comprise sorbitan trioleate Span-85, Tween 80 and vitamin E succinic acid polyethylene glycol ester. The prepared adjuvant influenza vaccine is good in immune effect, and especially the overall effect of the tetravalent adjuvant influenza vaccine on four viruses can be improved.

Ready to drink coffee beverages are provided. The beverage comprises coffee; medium chain triglycerides (MCT); high acyl gellan gum; plant-based protein; and buffer wherein coffee is 0.5-2.5 w / w %, and MCT is 5-10 w / w %. The beverage can be refrigerated and shelf-stable in a homogenous state for at least six months at 4, 20 and 30° C.

The invention belongs to the technical field of veterinary treatment medicines, and relates to a compound ivermectin juglone liniment as well as a preparation method and application thereof. The compound ivermectin juglone liniment is prepared from the following components in percentage by weight: 0.2 percent to 0.7 percent of juglone, 0.3 percent to 0.7 percent of ivermectin, 0.8 percent to 1 percent of tween-80, 0.1 percent to 0.15 percent of butylated hydroxytoluene, 0.2 percent to 5 percent of azone, 0.05 percent to 5 percent of menthol, 1 percent to 12 percent of isopropyl myristate and the balance of medium chain triglyceride, the compound ivermectin juglone liniment can be used for effectively removing parasites of animals, and is non-toxic and low in toxicity.

The invention discloses a stable cyclosporine ophthalmic ultra-micro emulsion, which comprises 0.1% of cyclosporine, 1%-2% of medium chain triglyceride, 0.4%-0.8% of an emulsifier, 2%-3% of glycerol, 0.0005%-0.005% of sitaammonium chloride and sodium hydroxide with a required amount for adjusting the pH value of the emulsion to 6.1-7.9, and the emulsifier is a combination of teloxaben and poloxamer in a weight ratio of 3: 1. The cyclosporin ophthalmic ultra-micro emulsion provided by the invention is smaller in droplet particle size and higher in Zeta potential, is basically not changed after being placed for a long time, and has better stability and better expected drug effect.

Compositions and methods for providing a person with an exogenous and therapeutically effective supply of medium chain triglycerides and short chain fatty acids are disclosed. The compositions include one or more medium chain triglycerides (particularly caprylic acid) combined with one or more short chain fatty acids, such as butyric acid, butyrate salts, propionic acid, propionate salts, acetoacetate, or acetate salts. The compositions and methods are useful for inducing ketosis and weight loss, as well as supporting healthy blood sugar levels, in a person.